Stayble Therapeutics AB (publ) (STABL.ST)
SEK 0.39
(1.56%)
SEK 0.39
(1.56%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -23.95 Million SEK | 3.4% |
| 2022 | -24.79 Million SEK | -104.26% |
| 2021 | -12.13 Million SEK | 18.66% |
| 2020 | -14.92 Million SEK | -117.1% |
| 2019 | -6.87 Million SEK | -12.34% |
| 2018 | -6.11 Million SEK | -118.75% |
| 2017 | -2.79 Million SEK | -135.42% |
| 2016 | -1.18 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -3.81 Million SEK | 41.97% |
| 2024 Q2 | -3.7 Million SEK | 2.94% |
| 2023 FY | -24 Million SEK | 3.2% |
| 2023 Q3 | -6.86 Million SEK | 0.13% |
| 2023 Q1 | -3.76 Million SEK | 18.35% |
| 2023 Q2 | -6.87 Million SEK | -82.42% |
| 2023 Q4 | -6.57 Million SEK | 4.21% |
| 2022 FY | -24.79 Million SEK | -104.26% |
| 2022 Q3 | -6.06 Million SEK | 8.4% |
| 2022 Q2 | -6.62 Million SEK | 11.73% |
| 2022 Q1 | -7.5 Million SEK | -63.58% |
| 2022 Q4 | -4.61 Million SEK | 23.94% |
| 2021 Q1 | -2.12 Million SEK | -132.35% |
| 2021 FY | -12.13 Million SEK | 18.66% |
| 2021 Q3 | -3.04 Million SEK | -27.95% |
| 2021 Q2 | -2.38 Million SEK | -12.19% |
| 2021 Q4 | -4.58 Million SEK | -50.37% |
| 2020 Q1 | -5.04 Million SEK | -63.04% |
| 2020 Q2 | -6.32 Million SEK | -25.4% |
| 2020 Q4 | -914.12 Thousand SEK | 65.43% |
| 2020 FY | -14.92 Million SEK | -117.1% |
| 2020 Q3 | -2.64 Million SEK | 58.19% |
| 2019 Q2 | -1.21 Million SEK | -8193.33% |
| 2019 Q1 | 15 Thousand SEK | 101.63% |
| 2019 Q4 | -3.09 Million SEK | -315.19% |
| 2019 FY | -6.87 Million SEK | -12.34% |
| 2019 Q3 | -745 Thousand SEK | 38.63% |
| 2018 Q4 | -920.1 Thousand SEK | 0.0% |
| 2018 FY | -6.11 Million SEK | -118.75% |
| 2017 FY | -2.79 Million SEK | -135.42% |
| 2016 FY | -1.18 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 90.379% |
| Ziccum AB (publ) | -21.56 Million SEK | -11.105% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -46.054% |
| BioArctic AB (publ) | 252.64 Million SEK | 109.482% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -2734.825% |
| Mendus AB (publ) | -100.65 Million SEK | 76.2% |
| Genovis AB (publ.) | 54.22 Million SEK | 144.177% |
| Intervacc AB (publ) | -93.57 Million SEK | 74.402% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -54.424% |
| Active Biotech AB (publ) | -46.48 Million SEK | 48.468% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 233.013% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 56.775% |
| Aptahem AB (publ) | -10.1 Million SEK | -137.059% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 92.549% |
| Kancera AB (publ) | -65.04 Million SEK | 63.171% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 82.206% |
| Fluicell AB (publ) | -26.87 Million SEK | 10.881% |
| Saniona AB (publ) | -81.06 Million SEK | 70.451% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -93.632% |
| Biovica International AB (publ) | -126.07 Million SEK | 81.0% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 43.644% |
| AcouSort AB (publ) | -17.48 Million SEK | -36.983% |
| Xintela AB (publ) | -57.23 Million SEK | 58.15% |
| Abliva AB (publ) | -96.54 Million SEK | 75.189% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 92.625% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -583.431% |
| OncoZenge AB (publ) | -15.9 Million SEK | -50.637% |
| Amniotics AB (publ) | -29.07 Million SEK | 17.606% |
| 2cureX AB (publ) | -36.36 Million SEK | 34.125% |
| CombiGene AB (publ) | -36.3 Million SEK | 34.02% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -63.622% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 93.768% |
| Camurus AB (publ) | 532.35 Million SEK | 104.5% |
| Corline Biomedical AB | -1.78 Million SEK | -1239.724% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 86.748% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 42.532% |
| I-Tech AB | 24.43 Million SEK | 198.033% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 96.962% |
| Cyxone AB (publ) | -21.66 Million SEK | -10.587% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 77.394% |
| Biosergen AB | -27.26 Million SEK | 12.143% |
| Cantargia AB (publ) | -290.01 Million SEK | 91.74% |
| NextCell Pharma AB | -43.17 Million SEK | 44.514% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 86.748% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -40.114% |
| Nanologica AB (publ) | -69.96 Million SEK | 65.762% |
| SynAct Pharma AB | -224.49 Million SEK | 89.33% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 45.775% |
| LIDDS AB (publ) | -40.67 Million SEK | 41.107% |
| Lipum AB (publ) | -37.25 Million SEK | 35.7% |
| BioInvent International AB (publ) | -369.94 Million SEK | 93.525% |
| Alzinova AB (publ) | -16.52 Million SEK | -44.984% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 90.549% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -274.681% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 79.183% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -18.945% |
| Simris Alg AB (publ) | -36.63 Million SEK | 34.614% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 83.656% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 92.283% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 78.403% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -107.109% |